Report: AstraZeneca's COVID-19 Vaccine Generates Antibodies and T-Cells Against the Virus in Phase I Trial

Phase I data from the COVID-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.

On Wednesday, U.K. media began to report hints of data from the early-stage study of the vaccine candidate that was provided by an unnamed “senior source.”